Histone acetylation plays an important role in the silencing and activation of genes involved in tumoregenesis. Trichostatin A, originally identified as an anti-fungal drug, is a potent inhibitor of histone deacetylase (HDAC) with potential anti-tumor activity. In this study, we investigated the effect of M344, an amide analogues of trichostatin A, on the growth and differentiation of THP-1 human leukemia cells. We showed that at low doses, (< 0.2 μM), M344 could inhibit the growth of THP-1 cells at G1 phase in vitro with low cytotoxic effect. Low dose of M344 exerted some differentiating effect on THP-1 cells as judged by the expression of c-fms proto-oncogene (M-CSF receptor) and appearance of adherent cells. Growth arrest induced by M...
The mRNA and protein levels of RKIP are reduced and those of YY1 increased in clinical HCC. Loss, mu...
Histone deacetylase (HDAC) inhibitors are a new class of epigenetic agents that were reported to enh...
Aim: Histone deacetylase inhibitors (HDACIs)-based therapies have stimulated interest via their anti...
Histone deacetylase inhibitors (HDACi) have demonstrated promising therapeutic potential in clinical...
Histone deacetylases (HDACs) inhibitors induce cell growth arrest and apoptosis in a wide variety of...
Background Histone deacetylase (HDAC) inhibitors are a group of small chemical molecules that inhibi...
In cells with an altered p53 gene, the expression of p21WAF1/CIP1, a potent inhibitor of cyclin-depe...
Epigenetic alterations of the histone acetylation play an important role in the regulation of gene e...
The main goal of our study has been to analyze the efficiency of new anticancer drugs, specifically ...
Aberrant epigenetic regulation of gene expression contributes to tumor initiation and progression. S...
Histone deacetylase (HDACAC) inhibitors are a new class of epigenetic agents that were reported to e...
Trichostatin A (TSA), an antifungal antibiotic derived from Streptomyces, inhibits mammalian histone...
Abstract Background Epithelial-mesenchymal transition (EMT) may be one of the reasons for the failur...
AbstractThe histone deacetylase inhibitor trichostatin A (TSA) has been previously shown to block ce...
ObjectiveHistone deacetylase inhibitors mediate a potent growth-inhibitory effect in cancer cells th...
The mRNA and protein levels of RKIP are reduced and those of YY1 increased in clinical HCC. Loss, mu...
Histone deacetylase (HDAC) inhibitors are a new class of epigenetic agents that were reported to enh...
Aim: Histone deacetylase inhibitors (HDACIs)-based therapies have stimulated interest via their anti...
Histone deacetylase inhibitors (HDACi) have demonstrated promising therapeutic potential in clinical...
Histone deacetylases (HDACs) inhibitors induce cell growth arrest and apoptosis in a wide variety of...
Background Histone deacetylase (HDAC) inhibitors are a group of small chemical molecules that inhibi...
In cells with an altered p53 gene, the expression of p21WAF1/CIP1, a potent inhibitor of cyclin-depe...
Epigenetic alterations of the histone acetylation play an important role in the regulation of gene e...
The main goal of our study has been to analyze the efficiency of new anticancer drugs, specifically ...
Aberrant epigenetic regulation of gene expression contributes to tumor initiation and progression. S...
Histone deacetylase (HDACAC) inhibitors are a new class of epigenetic agents that were reported to e...
Trichostatin A (TSA), an antifungal antibiotic derived from Streptomyces, inhibits mammalian histone...
Abstract Background Epithelial-mesenchymal transition (EMT) may be one of the reasons for the failur...
AbstractThe histone deacetylase inhibitor trichostatin A (TSA) has been previously shown to block ce...
ObjectiveHistone deacetylase inhibitors mediate a potent growth-inhibitory effect in cancer cells th...
The mRNA and protein levels of RKIP are reduced and those of YY1 increased in clinical HCC. Loss, mu...
Histone deacetylase (HDAC) inhibitors are a new class of epigenetic agents that were reported to enh...
Aim: Histone deacetylase inhibitors (HDACIs)-based therapies have stimulated interest via their anti...